Correction

CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia (vol 43, pg 121, 2022)

ACTA PHARMACOLOGICA SINICA (2022)

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia (vol 43, pg 121, 2022)

Find Funding. Review Successful Grants.

Publish scientific posters with Peeref

导出引文

分享论文